Afatinib
Spezifikationen
439081-18-2CAS-Nummer
810-720-4EG-Nummer
(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamideIUPAC-Name
C24H25ClFN5O3Chemische Formel
485.9 g/molMolekulargewicht
Afatinib; 850140-72-6; BIBW2992; Tomtovok; BIBW 2992; BIBW-2992; afatinibum; NSC-750691; 41UD74L59M; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; CHEBI:61390; DTXSID20893451; (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-; (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((3S)-oxolan-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((3S)-tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; RefChem:56995; L01XE13; DTXCID301323466; 810-720-4; 439081-18-2; Tovok; (E/Z)-Afatinib; (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib (BIBW2992); Afatinib free base; Afatinib, Free Base; BIBW2992 (Tovok); MFCD12407405; C24H25ClFN5O3; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide; (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide; CHEMBL1173655; NSC750691; (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-[(3S)-tetrahydrofuran-3-yl]oxy-quinazolin-6-yl]-4-(dimethylamino)but-2-enamide; (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib [USAN]; Afatinib [USAN:INN]; (E/Z)-BIBW 2992; UNII-41UD74L59M; Afatinib E-Isomer; (S)-Afatinib; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; BIBW 2992;; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide; (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide; 850140-72-6 (free base); S1011; BIBW2992,Afatinib; Afatinib (USAN/INN); AFATINIB [INN]; AFATINIB [MI]; AFATINIB [VANDF]; AFATINIB [MART.]; AFATINIB [WHO-DD]; (E/Z)-Afatinib (Standard); Afatinib - Bio-X trade mark; MLS006010000; orb322739; SCHEMBL232772; EX-A065A; GTPL5667; orb1225050; orb1306404; orb3141335; BIBW2992 (AFATINIB); SCHEMBL29388685; SCHEMBL29395096; CHEBI:94698; EX-A065; ULXXDDBFHOBEHA-CWDCEQMOSA-N; BIBW 29 92; GLXC-21899; GLXC-90096; HY-10261BR; BDBM50322823; BIBW2992AFATINIBTOVOKS1011; EBC-12394; HY-10261B; MFCD31630115; MSK162749; NSC799327; AKOS015850681; AKOS015904219; AKOS025149636; CCG-264776; DB08916; EX-8656; FC17230; NSC-799327; SDCCGSBI-0654325.P001; NCGC00185000-01; NCGC00185000-15; NCGC00185000-22; NCGC00185000-23; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide.; AC-26079; AC-27018; AS-80916; BA164141; BP-43626; DS-14172; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; SMR004701084; SY028094; SY047316; A2870; CS-0020030; NS00077621; SW219248-1; D09724; T21312; AB01565886_02; EN300-6487482; EN300-19625328; F050665; SR-01000941576; Q4688818; SR-01000941576-1; BRD-K66175015-001-01-7; BRD-K66175015-001-09-0; BRD-K66175015-001-13-2; BRD-K66175015-332-01-6; Z2568727518; (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-{[(3S)-oxolan-3-yl]oxy}quinazolin-6-yl]-4-(dimethylamino)but-2-enamide; (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide; (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(S)-tetrahydrofuran-3-yl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide; (S)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3-tetrahydrofuranyl)oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-; BIBW2992; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2E-butenamideSynonyme
Produkte, die Afatinib enthalten
GIOTRIF 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGIOTRIF 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGIOTRIF 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGIOTRIF 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGiotrifGiotrifGiotrifAFATIN 20AFATIN 40Strongfil-20Strongfil-30Strongfil-40
Seite 1 von 2
Unternehmen, die Afatinib verkaufen
BI
Boehringer Ingelheim International GmbhGermany
SF
Shanghai Famo Biotechnology Co.,Ltd.ChinaHD
Hangzhou Dingyan Chem Co., LtdChinaSS
Shanghai Sunway Pharmaceutical Technoiogy Co.,LtdChinaHH
Hefei Home Sunshine Pharmaceutical Technology Co.,LtdChinaAC
AFINE CHEMICALS LIMITED